30 closest matches · ranked by relevance
Chronic Ocular Graft-versus-host Disease
Primary: Modified SANDE Questionnaire - Frequency, Change From Baseline — -22.00; -4.59 score on a scale — p=0.0197
Ocular GVHD
Primary: Ocular Burning Sensation, Ocular Discharge, Ocular Redness, Ocular Itching, Foreign Body Sensation — 3.50; 2.23; 0.16; 0.26 units on a scale — p=0.0019
Dry Eyes
Primary: Progression of Dry Eye Severity — 15; 12 patients with increased dry eye severity
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Graft Versus Host Disease · Ophthalmologic Complications
Primary: Change in Patient-reported Symptoms Measured by the 8-point Lee Eye Subscale — 75.4; 63.2; 61.8; 56.3 units on a scale — p=0.01
Chronic Myeloproliferative Disorders · Graft Versus Host Disease · Leukemia
Primary: Number of Patients That Develop Ocular GVHD While on Study in the Two Arms (Ocular Cyclosporine (Restasis) vs. Placebo) — 9; 8 participants — p=>0.99
Ocular Graft Versus Host Disease
Primary: Overall Response Rate — 3; 6 eyes — p=0.375
Chronic Graft-versus-host Disease
Primary: Change From Baseline (Visit 1) of Total Corneal Fluorescein Staining Score at 12 Weeks. — -4.2; -6.2; -2.1 units on a scale
Oral Chronic Graft-versus-host Disease
Primary: The Clinical Efficacy of Topical Steroid and Topical Tacrolimus Therapies for the Treatment of Oral cGHVD. — 15; 3; 11; 2 participants
Acute Graft vs Host Disease · Allogeneic Bone Marrow Transplantation · Adverse Effects
Primary: Number of Participants Who Were Responders (CR, VGPR, or PR) on Day 28 With Low Cumulative Steroid Exposure — 41 Participants
Ocular Sarcoidosis · Panuveitis · Anterior Uveitis
Primary: Percentage of Patients With Clinically Significant Improvement in Visual Acuity — 3 Participants
Oral Chronic Graft vs Host Disease
Primary: Percentage of Participants With a Response as Assessed by the 273-point Oral Mucositis Rating Scale (OMRS) Who Received Topical Clobetasol 0.05% Oral Rinse for Oral…
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Chronic Graft Versus Host Disease
Primary: Number of Participants With an Overall Response at Week 28 — 20; 14 Participants — p=0.373
Graves' Ophthalmopathy
Primary: Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death During the 6-week Treatment…
Low Risk Acute Graft-versus-host Disease · Graft-versus-host-disease · GVHD
Primary: Number of Patients Who Achieve CR or PR by Day 28 of Treatment — 62 Participants
Graft Versus Host Disease
Primary: Day 56 Treatment Success — 57; 72; 43; 47 percentage of participants
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Keratoconjunctivitis Sicca
Primary: Tear Production — 16.6; 9.2 Percentage of eyes
Thyroid-associated Ophthalmopathy
Primary: Change in Clinical Activity Score (CAS) — -1.2; -1.5 units on a scale — p=0.73
Uveomeningoencephalitic Syndrome · Inflammation · Choroid Disease
Primary: Median Values of ERG Scotopic Parameters at 12-month — 201; 210; 508; 92 microvolts — p=<0.001
Hematological Malignancies
Primary: Incidence of Acute GVHD — 45.0 percentage of participants
Hematological Malignancies
Primary: Incidence of Clinician-diagnosed Chronic GVHD at One and Two Years — 38; 48 percentage of participants
Graft-versus-Host Disease · Immune System Disorders
Primary: GVHD-free Survival — 60; 69; 59; 47 participants
Cytomegalovirus Retinitis · HIV Infections
Primary: Survival — 31; 30 participants
Graft vs Host Disease
Primary: Number of Participants With the Ability to Successfully Taper Prednisone to a Dose Lower Dose. — 14 Participants
Graft vs. Host Disease
Primary: Corticosteroid-Requiring Chronic Graft-Versus-Host Disease (cGVHD) Rate — 13.3; 35.2 percentage of participants — p=0.0008
Hematologic Malignancies
Primary: GVHD-free Relapse-Free Survival — 19.3 percentage of subjects
Fuchs' Dystrophy · Corneal Edema
Primary: Intraocular Pressure — 11; 27 eyes